Admetsys’ FDA Breakthrough Designation Accelerates Arrival of Fully Autonomous Clinical Robotics in Hospital
BOSTON, Sept. 6, 2023 /PRNewswire/ — Admetsys Corporation, a biomedical technology company specializing in critical care automation, announced today that the FDA has designated its automated glucose control and continuous blood diagnostics system a Breakthrough Device. This designation accelerates the system’s path to market in the United States, where cardiometabolic disorder dominates critical care, and hospitals face increasing pressures from nursing shortages, escalating demand, and emphasis on equal access to high-quality care.
